CSPC Pharmaceuticals Receives Approval from NMPA for Clevidipine Injectable Emulsion
January 12, 2023
Trending News ☀️
Cspc Pharmaceutical Intrinsic Value – CSPC ($SEHK:01093) Pharmaceuticals is an established pharmaceutical company listed on the Hong Kong Stock Exchange. It is a leading producer of innovative medicines and health products in China. CSPC specializes in the research, development, manufacture and sale of medicines, medical devices and other health products. Recently, CSPC Pharmaceuticals has received approval from the National Medical Products Administration (NMPA) for its Clevidipine injectable emulsion. Clevidipine is an intravenous calcium channel blocker used to treat hypertension. It is the first injectable emulsion of its kind approved in China. CSPC Pharmaceuticals has invested heavily in research and development of innovative medicines and health products.
The approval of Clevidipine injectable emulsion reflects the company’s commitment to providing safe, effective and affordable healthcare solutions to the people of China. Clevidipine is expected to provide a much needed alternative to existing treatments for hypertension. It is a testament to the company’s commitment to innovation and quality. CSPC Pharmaceuticals is one of the leading companies in the health and medical industry in China, and its products are trusted by millions of people. The approval of Clevidipine injectable emulsion is a step forward in CSPC Pharmaceuticals’ mission to improve public health and expand access to high-quality healthcare solutions. The company is committed to providing safe, effective and affordable treatments for people around the world.
Price History
This marks a major milestone in the company’s progress and has resulted in a positive reaction from the media. The stock opened at HK$8.6 and closed at the same price, up 0.3% from the last closing price of 8.6. The NMPA approval is a significant achievement for CSPC, which has been working on this product for several years. Clevidipine Injectable Emulsion is a calcium channel blocker and is used to treat hypertension. It is a safe and effective medication that has been proven to be beneficial in lowering blood pressure.
CSPC has already established a strong presence in the Chinese market and the NMPA approval will further strengthen their position. The company is expected to benefit from increased sales and profits as a result of the approval. With this positive news, CSPC is likely to benefit from increased sales and profits in the coming months. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Cspc Pharmaceutical. More…
| Total Revenues | Net Income | Net Margin |
| 29.65k | 5.51k | 18.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cspc Pharmaceutical. More…
| Operations | Investing | Financing |
| 6.15k | -4.64k | -1.88k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cspc Pharmaceutical. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 38.84k | 9.42k | 2.35 |
Key Ratios Snapshot
Some of the financial key ratios for Cspc Pharmaceutical are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 12.4% | 15.7% | 23.3% |
| FCF Margin | ROE | ROA |
| 13.8% | 16.0% | 11.1% |
VI Analysis – Cspc Pharmaceutical Intrinsic Value Calculator
CSPC PHARMACEUTICAL is a company with strong fundamentals that reflect its long term potential. To help investors analyze the company more easily, VI app provides a simple overview. According to VI Line, the fair value of CSPC PHARMACEUTICAL shares is around HK$9.9. However, the current trading price of HK$8.6 is below this value, indicating that the stock is undervalued by 14%. Investors should note that CSPC PHARMACEUTICAL is a long-term investment opportunity and should not be judged by short-term market conditions. Therefore, it is important for investors to look at the fundamentals of the company such as their financials, operations, management, and competitive position in the industry. By doing this, investors can gain a better understanding of the company’s potential and decide whether it is worth investing in. Overall, CSPC PHARMACEUTICAL is a promising investment opportunity for investors who are looking for long-term gains. With its strong fundamentals, investors should take advantage of the current undervalued price and invest in CSPC PHARMACEUTICAL while they can. More…
VI Peers
The pharmaceutical industry is an intensely competitive sector, with CSPC Pharmaceutical Group Ltd competing against a range of powerful rivals, such as Hansoh Pharmaceutical Group Co Ltd, Luye Pharma Group Ltd and Evoke Pharma Inc. All four companies have significant resources and are constantly striving to gain market share in an ever-changing environment.
– Hansoh Pharmaceutical Group Co Ltd ($SEHK:03692)
Hansoh Pharmaceutical Group Co Ltd is a leading Chinese pharmaceutical company which focuses on the research, development, manufacturing and marketing of innovative pharmaceuticals. In 2022, the company had a market capitalization of 90.73 Billion US Dollars and a Return on Equity of 10.07%, indicating a strong financial performance. The company has been able to successfully utilize its resources to generate a strong financial return, which indicates a healthy and profitable business. This has allowed the company to expand its operations and develop new products, furthering its position as one of the leading pharmaceutical companies in the world.
– Luye Pharma Group Ltd ($SEHK:02186)
Luye Pharma Group Ltd is a pharmaceutical company based in China. It develops and manufactures pharmaceuticals, active pharmaceutical ingredients, and medical devices. As of 2022, the company has a market cap of 12.14 billion and a Return on Equity of 1.66%. This market cap indicates the company’s potential and size in the industry, while the Return on Equity provides an indication of the company’s profitability. Luye Pharma Group Ltd continues to be a major player in the pharmaceutical industry, developing innovative products and services that meet the needs of its customers.
– Evoke Pharma Inc ($NASDAQ:EVOK)
Evoke Pharma Inc is a specialty pharmaceutical company focused on treatments for gastrointestinal diseases. With a market cap of 6.22M as of 2022, Evoke Pharma is a smaller company compared to its peers. Additionally, the company has a Return on Equity of -74.6%, indicating that it is not generating profits from its shareholders’ investments. This could be due to the company’s focus on research and development of products instead of generating profits. The company’s share price has been volatile in recent months, so investors should consider the risks before investing in Evoke Pharma.
Summary
CSPC Pharmaceuticals has recently received approval from the China National Medical Product Administration (NMPA) for its Clevidipine Injectable Emulsion product. This approval makes CSPC the first Chinese pharmaceutical company to produce and market this drug globally. As a result, investors are increasingly interested in the potential of CSPC Pharmaceuticals. The company’s stock price has seen an increase since the news and is expected to continue to perform well in the future.
Furthermore, CSPC’s potential for developing additional drugs and expanding its existing product line may offer investors excellent long-term growth opportunities. Therefore, investors should consider adding CSPC Pharmaceuticals to their portfolios.
